{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:01:22Z","timestamp":1790136082664,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.bjid.2024.103867","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T04:57:06Z","timestamp":1726635426000},"page":"103867","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparative in vitro activity of Delafloxacin and other antimicrobials against isolates from patients with acute bacterial skin, skin-structure infection and osteomyelitis"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4997-0505","authenticated-orcid":false,"given":"\u00c1ghata Cardoso da Silva","family":"Ribeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Fernandes","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago Barcelos","family":"Valiatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Henrique","family":"Lenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid Nayara Marcelino","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8485-0576","authenticated-orcid":false,"given":"Ra\u00edssa Fidelis Ba\u00eata","family":"Neves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikechukwu Benjamin","family":"Moses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaqueline Pilon de","family":"Meneses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata Gebara de Grande","family":"Di Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5443-6024","authenticated-orcid":false,"given":"Mauro Jos\u00e9","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0913-768X","authenticated-orcid":false,"given":"Ana Cristina","family":"Gales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2024.103867_bib0001","first-page":"519","article-title":"Emerging treatment options for multi-drug-resistant bacterial infections","volume":"1","author":"Giurazza","year":"2021","journal-title":"Life (Basel)"},{"key":"10.1016\/j.bjid.2024.103867_bib0002","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3390\/pharmaceutics15030804","article-title":"Overview of side-effects of antibacterial fluoroquinolones: new drugs versus old drugs, a step forward in the safety profile?","volume":"15","author":"Rusu","year":"2013","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bjid.2024.103867_bib0003","unstructured":"Food and Drug Administration (FDA). Baxtela approval. 2019. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208610s000,208611s000lbl.pdf."},{"key":"10.1016\/j.bjid.2024.103867_bib0004","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2217\/fmb.15.39","article-title":"Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy","volume":"10","author":"Van Bambeke","year":"2015","journal-title":"Future Microbiol"},{"key":"10.1016\/j.bjid.2024.103867_bib0005","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3390\/antibiotics10121506","article-title":"Finafloxacin, and zabofloxacin: novel fluoroquinolones in the antibiotic pipeline","volume":"10","author":"Kocsis","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.bjid.2024.103867_bib0006","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1128\/AAC.47.10.3260-3269.2003","article-title":"In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone","volume":"47","author":"Nilius","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2024.103867_bib0007","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/jac\/dkh180","article-title":"Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492","volume":"53","author":"Harnett","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2024.103867_bib0008","doi-asserted-by":"crossref","first-page":"e02609","DOI":"10.1128\/AAC.02609-16","article-title":"In Vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"13","key":"10.1016\/j.bjid.2024.103867_bib0009","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s40265-017-0790-5","article-title":"Delafloxacin: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bjid.2024.103867_bib0010","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s13318-018-0520-8","article-title":"Clinical pharmacokinetics and pharmacodynamics of delafloxacin","volume":"44","author":"Shiu","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.bjid.2024.103867_bib0011","series-title":"Dra. Ivanete A. Dias Assi","article-title":"Delabaxi: delafloxacino meglumine [medicine leaflet]","year":"2020"},{"key":"10.1016\/j.bjid.2024.103867_bib0012","article-title":"The in vitro activity of delafloxacin and comparator agents against bacterial pathogens isolated from patients with cancer","volume":"5","author":"Gerges","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.bjid.2024.103867_bib0013","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jgar.2020.09.027","article-title":"Update on the activity of delafloxacin against acute bacterial skin and skin-structure infection isolates from European hospitals (2014-2019)","volume":"23","author":"Shortridge","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.bjid.2024.103867_bib0014","first-page":"114","volume":"54","author":"Nicola","year":"2022","journal-title":"Rev Argent Microbiol"},{"key":"10.1016\/j.bjid.2024.103867_bib0015","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.diagmicrobio.2013.06.011","article-title":"Performance of MALDI-ToF MS for species identification of Burkholderia cepacia complex clinical isolates","volume":"77","author":"Fehlberg","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.bjid.2024.103867_bib0016","series-title":"BrCAST. Tabela-Pontos-de-Corte-Clinicos-BrCAST","year":"2021"},{"key":"10.1016\/j.bjid.2024.103867_bib0017","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0167-7012(00)00122-6","article-title":"A modified microtiter-plate test for quantification of staphylococcal biofilm formation","volume":"40","author":"Stepanovic","year":"2000","journal-title":"J Microbiol Methods"},{"key":"10.1016\/j.bjid.2024.103867_bib0018","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1128\/JCM.43.10.5026-5033.2005","article-title":"Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus","volume":"43","author":"Zhang","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.bjid.2024.103867_bib0019","unstructured":"Melinta Therapeutics. Baxdela (delafloxacin) prescribing information. Melinta Therapeutics. 2019."},{"key":"10.1016\/j.bjid.2024.103867_bib0020","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.amjms.2022.01.016","article-title":"Early clinical experience with delafloxacin: a case series","volume":"363","author":"Hornak","year":"2022","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.bjid.2024.103867_bib0021","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jgar.2023.01.004","article-title":"Postoperative linezolid-resistant methicillin-resistant Staphylococcus epidermidis mediastinitis in a heart transplant patient: first case of therapeutic success with delafloxacin","volume":"32","author":"Bouchand","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"issue":"Suppl 2","key":"10.1016\/j.bjid.2024.103867_bib0022","article-title":"P41 Use of delafloxacin in osteomyelitis: a case report","volume":"5","author":"Vidwans","year":"2023","journal-title":"JAC Antimicrob Resist"},{"issue":"S1","key":"10.1016\/j.bjid.2024.103867_bib0023","article-title":"Delafloxacino para o tratamento de infec\u00e7\u00f5es complicadas de pele e partes moles","volume":"27","author":"Ito","year":"2023","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.bjid.2024.103867_bib0024","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00772-17","article-title":"In Vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections","volume":"61","author":"McCurdy","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"S1","key":"10.1016\/j.bjid.2024.103867_bib0025","article-title":"Avalia\u00e7\u00e3o Da atividade in vitro de delafloxacino frente a staphylococcus aureus de pacientes internados em hospital terci\u00e1rio no sul do Brasil","volume":"27","author":"Barth","year":"2023","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.bjid.2024.103867_bib0026","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/crj.13262","article-title":"Delafloxacin \u2012 a novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis","volume":"15","author":"Millar","year":"2021","journal-title":"Clin Resp J"},{"key":"10.1016\/j.bjid.2024.103867_bib0027","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1186\/cc3995","article-title":"Toxicity of polymyxins: a systematic review of the evidence from old and recent studies","volume":"10","author":"Falagas","year":"2006","journal-title":"Crit Care (London, England)"},{"key":"10.1016\/j.bjid.2024.103867_bib0028","article-title":"Delafloxacin and Comparator Fluoroquinolones In Vitro Resistance Trends in Isolates from Skin and Skin Structure Infections in the USA (2017\u20132022)","author":"Huband","year":"2023","journal-title":"IDWeek"},{"issue":"7","key":"10.1016\/j.bjid.2024.103867_bib0029","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1093\/cid\/ciz1095","article-title":"An emerging clone, klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae sequence type 16, associated with high mortality rates in a CC258-endemic setting","volume":"71","author":"Andrey","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2024.103867_bib0030","series-title":"Kucers\u2019 The Use of Antibiotics","first-page":"2132","article-title":"Delafloxacin","author":"Mangalore","year":"2018"},{"key":"10.1016\/j.bjid.2024.103867_bib0031","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/antibiotics12010087","article-title":"Antimicrobial treatment of staphylococcus aureus biofilms","volume":"12","author":"Tuon","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.bjid.2024.103867_bib0032","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.3390\/jcm10081743","article-title":"New-generation antibiotics for treatment of gram-positive infections: a review with focus on endocarditis and osteomyelitis","volume":"10","author":"Bloem","year":"2021","journal-title":"J Clin Med"},{"issue":"S1","key":"10.1016\/j.bjid.2024.103867_bib0033","article-title":"Osteomielite sacral- infec\u00e7\u00e3o de dif\u00edcil tratamento","volume":"27","author":"Fernandes","year":"2023","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.bjid.2024.103867_bib0034","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.00181-13","article-title":"A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms","volume":"57","author":"Bauer","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2024.103867_bib0035","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1128\/AAC.03482-14","article-title":"Comparison of the antibiotic activities of daptomycin, vancomycin, and the investigational fluoroquinolone delafloxacin against biofilms from staphylococcus aureus clinical isolates","volume":"58","author":"Siala","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2024.103867_bib0036","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/nyas.12830","article-title":"Mechanisms of drug resistance: quinolone resistance","volume":"1354","author":"Hooper","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bjid.2024.103867_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.835403","article-title":"Genetic diversity, distribution, and genomic characterization of antibiotic resistance and virulence of clinical pseudomonas aeruginosa strains in Kenya","volume":"13","author":"Kiyaga","year":"2022","journal-title":"Front Microbiol"},{"issue":"4","key":"10.1016\/j.bjid.2024.103867_bib0038","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1590\/S1517-83822012000400010","article-title":"Mutations in the quinolone resistance-determining regions of gyrA and parC in Enterobacteriaceae isolates from Brazil","volume":"43","author":"Minarini","year":"2012","journal-title":"Braz J Microbiol"},{"issue":"10","key":"10.1016\/j.bjid.2024.103867_bib0039","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1128\/AAC.47.10.3222-3232.2003","article-title":"Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections","volume":"47","author":"Komp Lindgren","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2024.103867_bib0040","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.bjm.2016.07.016","article-title":"The role of gyrA and parC mutations in fluoroquinolones-resistant Pseudomonas aeruginosa isolates from Iran","volume":"47","author":"Nouri","year":"2016","journal-title":"Braz J Microbio"},{"key":"10.1016\/j.bjid.2024.103867_bib0041","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/cid\/ciy600","article-title":"Delafloxacin: a New Anti-methicillin-resistant Staphylococcus aureus Fluoroquinolone","volume":"68","author":"Saravolatz","year":"2019","journal-title":"Clin Infect Dis"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867024001508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867024001508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T15:28:40Z","timestamp":1733153320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1413867024001508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1413867024001508"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2024.103867","relation":{},"ISSN":["1413-8670"],"issn-type":[{"value":"1413-8670","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative in vitro activity of Delafloxacin and other antimicrobials against isolates from patients with acute bacterial skin, skin-structure infection and osteomyelitis","name":"articletitle","label":"Article Title"},{"value":"The Brazilian Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjid.2024.103867","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedade Brasileira de Infectologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"103867"}}